111In-XYIMSR-01 for Kidney Cancer

This trial tests a new radiotracer, 111In-XYIMSR-01, to determine its effectiveness in detecting kidney cancer, specifically clear cell renal cell carcinoma, during a SPECT-CT scan. The main goal is to enhance the detection of cancerous tissue through advanced imaging. This trial may suit individuals diagnosed with clear cell kidney cancer who have multiple disease sites visible on recent scans. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new radiotracer.

The trial does not specify if you need to stop taking your current medications. However, you cannot have had systemic therapy for kidney cancer within the last 12 months or any radioisotope treatment recently.

Research shows that 111In-XYIMSR-01 is being tested for safety and side effects using a special scan called SPECT/CT, which helps doctors see kidney cancer more clearly. In earlier studies, scientists examined how the body processes this treatment and checked for any harmful effects. These studies ensure the treatment can be safely tested in humans.

Unlike the standard treatments for kidney cancer, which typically include surgery, chemotherapy, and targeted therapies like tyrosine kinase inhibitors, 111In-XYIMSR-01 introduces a novel approach by using a radioactive tracer combined with SPECT/CT imaging. This treatment is unique because it leverages a radiopharmaceutical agent that specifically targets cancer cells, potentially allowing for both precise imaging and targeted therapy. Researchers are excited about this treatment because it could offer more accurate detection and treatment of kidney cancer, potentially leading to better outcomes and fewer side effects compared to conventional therapies.

Research has shown that 111In-XYIMSR-01, the investigational treatment in this trial, is a promising tool for detecting tumors in kidney cancer. It targets a protein called carbonic anhydrase IX, which is abundant in clear cell renal cell carcinoma, a type of kidney cancer. Early results indicate that this agent effectively highlights cancer cells during scans. Studies have consistently detected tumors with high levels of carbonic anhydrase IX using this agent, suggesting it could reliably identify kidney cancer. This evidence supports the use of 111In-XYIMSR-01 as an effective method for locating cancerous areas in the body during scans.¹³⁴⁵⁶